Mixed connective tissue disease secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 18: Line 18:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]
[[Category:Medicine]]
[[Category:Up-To-Date]]
[[Category:Rheumatology]]

Revision as of 13:46, 20 April 2018

Mixed connective tissue disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mixed connective tissue disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mixed connective tissue disease secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mixed connective tissue disease secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Mixed connective tissue disease secondary prevention

on Mixed connective tissue disease secondary prevention

Mixed connective tissue disease secondary prevention in the news

Blogs onMixed connective tissue disease secondary prevention

Directions to Hospitals Treating Mixed connective tissue disease

Risk calculators and risk factors for Mixed connective tissue disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

In MCTD effective measures for the secondary prevention of Raynaud's disease include vasodilator therapies (such as calcium channel blockers), preventive measures like avoidance of cold temperatures and other triggering factors (such as smoking and sympathomimetic agents) and use of warm and protection techniques of fingers. Current strategies include Bosentan (endothelin receptor antagonist) as the recommended medication for the prevention of new digital ulcers.

Secondary Prevention

References

  1. Ortega-Hernandez OD, Shoenfeld Y (February 2012). "Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment". Best Pract Res Clin Rheumatol. 26 (1): 61–72. doi:10.1016/j.berh.2012.01.009. PMID 22424193.

Template:WH Template:WS